Dyne Therapeutics, Inc. $DYN Shares Bought by Squarepoint Ops LLC

Squarepoint Ops LLC raised its position in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 334.3% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 181,740 shares of the company’s stock after purchasing an additional 139,896 shares during the quarter. Squarepoint Ops LLC’s holdings in Dyne Therapeutics were worth $1,730,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Thrivent Financial for Lutherans acquired a new stake in Dyne Therapeutics during the 2nd quarter worth approximately $420,000. Caxton Associates LLP increased its position in shares of Dyne Therapeutics by 10.9% in the second quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock worth $158,000 after acquiring an additional 1,627 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of Dyne Therapeutics by 275.1% in the second quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock worth $100,000 after acquiring an additional 7,697 shares in the last quarter. Wasatch Advisors LP raised its stake in shares of Dyne Therapeutics by 9.2% in the 2nd quarter. Wasatch Advisors LP now owns 557,937 shares of the company’s stock valued at $5,312,000 after acquiring an additional 46,889 shares during the period. Finally, Frazier Life Sciences Management L.P. lifted its holdings in shares of Dyne Therapeutics by 4.3% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 1,505,984 shares of the company’s stock valued at $14,337,000 after acquiring an additional 62,643 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. HC Wainwright increased their price target on Dyne Therapeutics from $46.00 to $60.00 and gave the company a “buy” rating in a report on Monday, December 8th. Lifesci Capital upgraded Dyne Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 14th. Morgan Stanley raised their target price on Dyne Therapeutics from $46.00 to $50.00 and gave the company an “overweight” rating in a report on Monday, December 8th. Wall Street Zen raised Dyne Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Evercore ISI lowered their price objective on shares of Dyne Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Monday. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.47.

Dyne Therapeutics Trading Up 7.0%

Shares of DYN opened at $19.85 on Friday. The company has a market capitalization of $2.83 billion, a P/E ratio of -5.42 and a beta of 1.30. Dyne Therapeutics, Inc. has a one year low of $6.36 and a one year high of $26.22. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.47 and a current ratio of 13.47. The stock has a 50-day moving average price of $19.70 and a 200 day moving average price of $14.52.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.05. Sell-side analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.